Sk Kumar

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway
    Vijay Ramakrishnan
    The Divisions of Hematology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e50005. 2012
  2. pmc Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
    S Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:943-9. 2011
  3. pmc Efficacy of bortezomib as first-line treatment for patients with multiple myeloma
    Utkarsh Painuly
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA 4th Department of Internal Medicine, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czech Republic
    Clin Med Insights Oncol 7:53-73. 2013
  4. pmc Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Invest New Drugs 31:1201-6. 2013
  5. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
  6. doi Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4375-82. 2012
  7. pmc Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 119:2100-5. 2012
  8. pmc Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 30:989-95. 2012
  9. pmc Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:1585-92. 2012
  10. pmc Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
    S K Kumar
    Divison of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:149-57. 2012

Detail Information

Publications82

  1. pmc Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway
    Vijay Ramakrishnan
    The Divisions of Hematology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e50005. 2012
    ..These provide the basis for clinical evaluation of MK-2206 alone or in combination in MM and potential use of baseline pAkt and pErk as biomarkers for patient selection...
  2. pmc Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
    S Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:943-9. 2011
    ..This study suggests that PB-CD34 thresholds should be based on collection target to allow for early intervention and to prevent collection failures...
  3. pmc Efficacy of bortezomib as first-line treatment for patients with multiple myeloma
    Utkarsh Painuly
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA 4th Department of Internal Medicine, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czech Republic
    Clin Med Insights Oncol 7:53-73. 2013
    ..This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma...
  4. pmc Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Invest New Drugs 31:1201-6. 2013
    ..Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models...
  5. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
    ..The trial was registered at www.clinicaltrials.gov (NCT00564889)...
  6. doi Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4375-82. 2012
    ..No substantial advantage was noted with VDCR over the 3-drug combinations. This trial is registered at www.clinicaltrials.gov (NCT00507442)...
  7. pmc Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 119:2100-5. 2012
    ..Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers...
  8. pmc Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 30:989-95. 2012
    ..However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification...
  9. pmc Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:1585-92. 2012
    ..It is not clear whether this paradigm holds true in the context of new therapies, such as immunomodulatory drugs (IMiDs)...
  10. pmc Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
    S K Kumar
    Divison of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:149-57. 2012
    ..This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs...
  11. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  12. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  13. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  14. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...
  15. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  16. ncbi Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:2035-42. 2007
    ..We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures...
  17. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  18. ncbi Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55906, USA
    Blood 114:1729-35. 2009
    ....
  19. pmc Stem cell transplantation for multiple myeloma
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Oncol 21:162-70. 2009
    ..This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies...
  20. ncbi Treatment of newly diagnosed multiple myeloma: advances in current therapy
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    Med Oncol 27:S14-24. 2010
    ..This article summarizes the recent advances in the treatment of newly diagnosed myeloma and suggests a treatment algorithm for approaching newly diagnosed myeloma...
  21. doi Role of autologous stem cell transplantation in multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 2:121-7. 2007
    ..The role of ASCT will clearly be redefined in the coming years with improvements in other therapies...
  22. doi Impact of early relapse after auto-SCT for multiple myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:413-20. 2008
    ..Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches...
  23. pmc Impact of additional cytoreduction following autologous SCT in multiple myeloma
    Sk Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:259-64. 2008
    ....
  24. doi Role of allogeneic stem cell transplantation in multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 3:99-106. 2008
    ..Patients with high-risk genetic and biochemical features do poorly with conventional therapies, and allogeneic transplantation offers the potential for long-term disease control...
  25. ncbi Multiple myeloma - current issues and controversies
    Shaji Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Treat Rev 36:S3-11. 2010
    ..While we still lack definitive data answering some of these questions, we have attempted to interpret the current state of knowledge, and provide a perspective on the current issues and controversies in this disease...
  26. doi Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
    S K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:1013-9. 2008
    ..6 months for Dex and were not reached for Thal-Dex and Len-Dex groups, P=0.2. For patients undergoing early ASCT for myeloma, the nature of initial treatment utilized has no long-term impact on the outcome of ASCT...
  27. doi Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:205-11. 2008
    ..Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma...
  28. ncbi Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  29. doi Treatment of newly diagnosed multiple myeloma in transplant-eligible patients
    Shaji Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 6:104-12. 2011
    ..In addition, the newer drugs are being explored as maintenance therapy following SCT. This review summarizes the current approach to the treatment of newly diagnosed myeloma in transplant-eligible patients...
  30. pmc Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1350-6. 2010
    ..VDCR is well tolerated and highly active in this population. No MTD was reached; the recommended phase 2 cyclophosphamide dose in VDCR is 500 mg/m(2), which was the highest dose tested...
  31. pmc Immunophenotyping in multiple myeloma and related plasma cell disorders
    Shaji Kumar
    Divisions of Hematology and Hematopathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States
    Best Pract Res Clin Haematol 23:433-51. 2010
    ..This book chapter addresses the approaches taken to evaluate monoclonal plasma cell disorders, and the different markers and techniques that are important for the study of these diseases...
  32. ncbi Progress in the treatment of multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 367:791-2. 2006
  33. pmc Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
    Shaji K Kumar
    Division of Hematology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Blood 118:4359-62. 2011
    ..74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475...
  34. ncbi Thalidomide and dexamethasone: therapy for multiple myeloma
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 5:759-66. 2005
    ..Thalidomide analogs with a better safety profile are currently undergoing evaluation in the clinic...
  35. ncbi Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
    Shaji K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:614-7. 2008
    ..The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age...
  36. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  37. ncbi High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:161-7. 2004
    ..65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT...
  38. doi Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...
  39. ncbi Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Hematol 81:215-8. 2002
    ..This report describes a patient with agnogenic myeloid metaplasia and Klinefelter syndrome, an association not previously reported...
  40. ncbi A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  41. ncbi Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Hematol 80:430-5. 2001
    ..Here we describe a patient who developed pneumomediastinum, pneumopericardium, subcutaneous emphysema and pneumothorax secondary to severe bronchiolitis obliterans complicating the post bone marrow transplantation course...
  42. ncbi Thalidomide as initial therapy for early-stage myeloma
    S V Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 17:775-9. 2003
    ..Thalidomide has significant activity in early-stage myeloma and has the potential to delay progression to symptomatic disease. This approach must be further tested in randomized trials...
  43. ncbi Treatment advances in adult immune thrombocytopenic purpura
    M R Huber
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Hematol 82:723-37. 2003
    ..In this review, we will examine treatment for chronic ITP in adults in the pre-splenectomy, splenectomy, and post-splenectomy settings...
  44. ncbi Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 39:605-11. 2007
    ..Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation...
  45. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
    ..The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma...
  46. ncbi CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 19:1466-70. 2005
    ..07). The expression of CD138, CD56 and CD54 were higher among the CD45- PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells...
  47. ncbi Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 30:161-5. 2002
    ..03). Relapse-free survival was similar for the two groups. We conclude that omitting day +11 MTX appears to increase the risk of severe acute GVHD...
  48. ncbi Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:624-7. 2004
    ..Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma...
  49. ncbi Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:235-9. 2004
    ..007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma...
  50. ncbi Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:951-6. 2001
    ..002). We conclude that a slow lymphocyte recovery after allogeneic BMT for AML is strongly predictive of subsequent relapse and that the type of GVHD prophylaxis should be considered when analyzing lymphocyte recovery...
  51. ncbi Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:485-90. 2004
    ..18. No significant differences were observed in the progression-free and overall survival at 1 year post transplant. Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma...
  52. ncbi Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation
    S A Capizzi
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 27:1299-303. 2001
    ..The rapid response to corticosteroid treatment and the fact that such therapy was delayed until after intubation in all the mechanically ventilated cases point to a therapeutic benefit...
  53. ncbi Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Bone Marrow Transplant 27:1133-40. 2001
    ..We conclude that GVHD prophylaxis with CYA-PRED is associated with a higher overall rate of cGVHD compared to CYA-MTX. The type of GVHD prophylaxis should be considered when comparing the incidence of cGVHD reported in different studies...
  54. ncbi Thalidomide as an anti-cancer agent
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Cell Mol Med 6:160-74. 2002
    ..We have concisely reviewed the current knowledge regarding mechanisms of its anti-neoplastic activity and the results of various clinical trials in oncology...
  55. ncbi Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 16:1311-8. 2002
    ..0009; 105 vs 9 months, P < 0.0008, respectively). In conclusion, ALC > or =500 cells/microl on day 15 post-AHSCT is associated with better survival in acute myelogenous leukemia and requires further studies...
  56. ncbi Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:1865-70. 2003
    ..Such patients could be considered for interventions aimed at prevention of relapse, including rapid withdrawal of immunosuppressive medication or donor lymphocyte infusion...
  57. pmc Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
    V Ramakrishnan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Oncogene 29:1190-202. 2010
    ..Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations...
  58. ncbi High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:381-5. 2001
    ..The mean post-transplant hospital stay for those with GI tract bleeding was 37 days compared with 14.5 days for those who did not have GI tract bleeding (P = 0.0047)...
  59. pmc Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
    C L H Snozek
    Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:1933-7. 2008
    ..001). These findings suggest that the serum FLC ratio at initial diagnosis is an important predictor of prognosis in myeloma, and can be incorporated into the ISS for improved risk stratification...
  60. ncbi ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
    M P Kline
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 21:1549-60. 2007
    ..These data indicate that therapies targeting apoptotic pathways may be effective in MM treatment and warrant clinical evaluation of ABT-737 and similar drugs alone or in combination with other agents in the setting of MM...
  61. pmc GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study
    A D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurology 72:806-12. 2009
    ..The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone...
  62. ncbi Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands
    W A Aldrich
    Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA
    Gene Ther 13:29-39. 2006
    ..These studies demonstrate the potential utility of sc rAAV serotype 6-based vectors in transduction of DC for genetic vaccination approaches...
  63. ncbi Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 32:1065-9. 2003
    ..However, there was no significant change in MVD following transplant (P=0.8, paired t-test). Abnormal bone marrow angiogenesis appears to persist in the bone marrow following ASCT for CML, at least in the short term...
  64. ncbi Expression of VEGF and its receptors by myeloma cells
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:2025-31. 2003
    ..Demonstration of the presence of VEGFR2 in our study provides a potential biological explanation for the preclinical activity observed with VEGFR2 inhibitors...
  65. ncbi Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Hematol 81:312-9. 2002
    ..The current study provides additional data on both the long-term outcome of splenectomy in adults with ITP and the management of postsplenectomy relapse...
  66. ncbi Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:997-9. 2001
    ..Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action...
  67. ncbi Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions
    S C Tyagi
    Department of Internal Medicine, Dalton Cardiovascular Research Center, University of Missouri Health Sciences Center, Columbia, USA
    Can J Cardiol 12:353-62. 1996
    ..Expression of extracellular matrix (ECM), including collagens and proteoglycans, is increased following atherosclerosis and restenosis...
  68. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  69. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  70. ncbi High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:343-60. 2006
    ..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy...
  71. ncbi The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  72. ncbi In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  73. ncbi Serum M-spike and transplant outcome in patients with multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:1035-40. 2007
    ..The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease...
  74. doi Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Hilmi Ege
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 141:792-8. 2008
    ..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM...
  75. ncbi Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 2:440-4. 2007
    ..Achievement of renal response was associated with improved survival. These results suggest that early intervention with aggressive therapy is not only justified but recommended to achieve optimal response...
  76. ncbi Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 92:1415-8. 2007
    ..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival...
  77. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  78. pmc Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 111:785-9. 2008
    ..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
  79. ncbi Relationship between depth of response and outcome in multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:4933-7. 2007
    ..We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS...
  80. ncbi Clinical course of patients with relapsed multiple myeloma
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:867-74. 2004
    ..To study the clinical course of patients with multiple myeloma (MM) that relapses after initial therapy...
  81. ncbi Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  82. ncbi Malignant primary cardiac tumors: review of a single institution experience
    Lijo Simpson
    Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 112:2440-6. 2008
    ..Primary cardiac sarcomas are uncommon. The authors undertook to review the Mayo Clinic's experience with primary cardiac sarcomas consisting of 34 patients seen over a 32-year period...